Event Details |
Buprenorphine Waiver Training |
07/17/2018 |
8:00 am - 12:00 pm |
High Country Conference Center |
201 West Butler Avenue |
Flagstaff, Arizona, 86001 |
Event Description |
To prescribe buprenorphine, one of three medications approved by the FDA for the treatment of opioid use disorder, physicians are required to complete 8 hours of training in order to apply to the Drug Enforcement Agency for a waiver. This course will provide prescribers with the first 4 hours of required MAT training. Following completion of the course, attendees will be given a link to complete the remainder of the training at no cost from the Providers Clinical Support System (PCSS). Nurse Practitioners (NP) and Physician assistants (PA) are required to complete 24 hours of training including the 8 hour MAT training. Coffee and light refreshments will be provided.
Registration: $25 per person.
We provide continuing education through NAADAC http://www.naadac.org/ which is typically accepted by most licensing and certification bodies. Please contact cabhp@asu.edu with any questions.
AAAP is the Data Sponsor for this training. Funding for this course was made possible (in part) by 1U79TI026556 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government
Registration: $25 per person.
We provide continuing education through NAADAC http://www.naadac.org/ which is typically accepted by most licensing and certification bodies. Please contact cabhp@asu.edu with any questions.
AAAP is the Data Sponsor for this training. Funding for this course was made possible (in part) by 1U79TI026556 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government